Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

3.0K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.0K
Cancer Vaccines01:30

Cancer Vaccines

581
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
581
Cancer Survival Analysis01:21

Cancer Survival Analysis

481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated prostate specific antigen due to indwelling urethral catheterisation: myth or fact? A systematic review and meta-analysis.

World journal of urology·2026
Same author

Artificial intelligence in urology: A review of United States Food and Drug Administration-cleared devices.

BJU international·2026
Same author

Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.

European radiology·2026
Same author

PRECISE Version 2: Essential Tips for Prostate Cancer Monitoring Using MRI.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same author

Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer.

BMC urology·2026
Same author

Reply to the Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.

European radiology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Oct 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Prostate cancer.

Shahneen Sandhu1, Caroline M Moore2, Edmund Chiong3

  • 1Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Lancet (London, England)
|August 9, 2021
PubMed
Summary
This summary is machine-generated.

Advances in prostate cancer management include personalized therapeutics targeting DNA repair pathways and improved survival with novel androgen inhibitors for metastatic disease. Future research focuses on molecular characterization and novel treatments like radioisotopes and immunotherapy.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.6K

Related Experiment Videos

Last Updated: Oct 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.6K

Area of Science:

  • Oncology
  • Genitourinary Cancer Research

Background:

  • Prostate cancer management is rapidly evolving.
  • Understanding of genomic landscape and biology has advanced.
  • Sensitive imaging methods have improved diagnosis and staging.

Purpose of the Study:

  • To review recent advances in prostate cancer management.
  • To highlight the impact of personalized therapeutics and novel treatment strategies.
  • To discuss the future directions in prostate cancer research.

Main Methods:

  • Review of current literature and clinical practice.
  • Analysis of genomic and molecular characterization data.
  • Evaluation of emerging therapeutic approaches.

Main Results:

  • Personalized therapeutics targeting DNA repair pathways are validated.
  • Metastatic-directed therapies show promise for oligometastatic disease.
  • Novel androgen pathway inhibitors significantly improve survival in metastatic prostate cancer.

Conclusions:

  • Molecular characterization will impact clinical management of localized and advanced disease.
  • Targeted radioisotopes and immunotherapy offer promising future treatment options.
  • Continued research is crucial for improving patient outcomes in prostate cancer.